



Alizarin Red Quantifcation




Figure S1. Quantitative analysis of alizarin red by spectrophotometry showing no difference in osteogenic differentiation between healthy and lipedema ASCs-T or healthy and lipedema ASCs-A (n= 4 per group). Results are displayed as scatter plots with bar. Values are mean \pm SEM.




Figure S2. Flow cytometry analysis of SVFs. (A) SVFs showed a similar expression of stemness and surface markers between lipedema patients (SVF-A, n = 6; SVF-T, n = 8). (B) CD31 marker expression in SVFs showed a significant increase in lipedema patients compared to healthy patients (SVF-A healthy, n = 8; SVF-T lipedema, n = 6; SVF-A lipedema, n = 9). Results are displayed as scatter plots with bar. Values are mean \pm SEM. ** p < 0.01 *** p < 0.001.




Figure S3. Quantitative analysis of CFU assay revealed a significant increase in the colony-forming potential of lipedema ASCs compared with healthy patients as well as a significant decrease between healthy ASCs-T and lipedema ASCs-A (ASCs-T: healthy n = 8 and lipedema n = 10; ASCs-A: healthy n = 9 and lipedema n = 8). Results are displayed as scatter plots with bar. Values are mean \pm SEM. *p < 0.05, **p < 0.01.




Figure S4. Quantitative analysis of Oil Red O (A) and Alizarin red (B) by spectrophotometry showing a significant decrease in adipogenic and osteogenic differentiation potential in lipedema ASCs-A compared to lipedema ASCs-T (p < 0.05) and a significant decrease in the osteogenic potential in healthy ASCs-A compared to healthy ASCs-T, but no difference was shown in their adipogenic potential (Adipogenic differentiation ASCs-T: healthy n = 10 and lipedema n = 9, ASCs-A: n = 8 per group, Osteogenic differentiation, n = 4 per group).